Navigation Links
Phase III Trial of Novartis Drug Afinitor® Met Primary Endpoint of Reducing SEGA Tumor Size in Patients With Tuberous Sclerosis
Date:7/7/2011

EAST HANOVER, N.J., July 8, 2011 /PRNewswire/ -- Novartis Pharmaceuticals Corporation ("Novartis") announced today Phase III trial results that showed more than one-third of patients taking Afinitor® (everolimus) tablets* experienced a 50% or greater reduction in the size of their subependymal giant cell astrocytomas (SEGAs), non-cancerous brain tumors associated with tuberous sclerosis complex (TSC)(1,2,6). This study, the largest prospective clinical trial to date in this patient population, is being presented on Saturday, July 9 at the International TSC Research Conference in Washington, D.C.

Currently, Afinitor is approved in the US for the following indication: to treat patients with SEGA associated with tuberous sclerosis who require therapeutic intervention but are not candidates for curative surgical intervention. The effectiveness of everolimus is based on an analysis of change in SEGA volume. Additionally, the indication states, clinical benefit such as improvement in disease-related symptoms or increase in overall survival has not been shown(7).

Tuberous sclerosis complex affects approximately 25,000 to 40,000 people in the US and one to two million people worldwide, and is associated with a variety of resulting disorders including seizures, swelling in the brain (hydrocephalus), developmental delays and skin lesions(2,6). Also known as tuberous sclerosis (TS), TSC is a genetic disorder that may cause non-cancerous tumors to form in vital organs and can affect many different parts of the body, most commonly the brain and kidney(6,8). Signs and symptoms of TSC vary depending on which system and which organs are involved(6). SEGAs occur in up to 20% of patients with TSC. In countries where everolimus is not approved, brain surgery is the only treatment option for patients with growing SEGAs(2).

The 117-patient, randomized, placebo-controlled Phase III EXIST-1 (EXamining everolimus In a Study of TSC) trial met its primary endpoin
'/>"/>

SOURCE Novartis Pharmaceuticals Corporation
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13

Related medicine technology :

1. Ampio Pharmaceuticals Announces Treatment of First Patient in Phase 1b Ampion-In -Knee (AIK) Trial for Osteoarthritis in Australia
2. GlaxoSmithKline Implements Next Phase of New Incentive Compensation Program for U.S. Sales Representatives
3. Ataluren Phase 2 Data in Nonsense Mutation Cystic Fibrosis Published in the European Respiratory Journal
4. Endo Announces Topline Results From Phase 2 Study of Axomadol in Chronic Low Back Pain
5. Phase III Study Shows Once-Daily NVA237 is Superior to Placebo and Similar to Tiotropium in Improving Lung Function in COPD
6. DNA Medicine Institute Awarded Two Phase III SBIR NASA Contracts for Its rHEALTH Sensor
7. Phase I of the Swedish/Issaquah Medical Center Campus to Open in July
8. The Lancet Publishes Data from Protege, MacroGenics Phase 3 Clinical Study of Teplizumab in Type 1 Diabetes Patients
9. Morphotek®, Inc. Announces Initiation of Farletuzumab Phase II Study in First-Line Treatment of Non-Small Cell Lung Cancer
10. Palatin Technologies, Inc. Initiates Enrollment in Phase 2b Trial With Bremelanotide in Women With Female Sexual Dysfunction
11. Cardium Announces Plans to Acquire Transdel Pharmaceuticals Phase 3 Topical Analgesic and Cosmeceutical Business Assets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/22/2015)... 2015 According to a new ... (Consumables, Instruments, Services), by Test Type (Indirect, Enzyme-based, Reactive ... by End Users - Global Forecast to 2020", published ... to reach $736.85 Million by 2020 from $452.36 Million ... Browse 71 market data Tables and 90 ...
(Date:5/22/2015)...  In a sweeping analysis assessing the current state ... researchers conclude that there remains considerable room for ... age groups, but especially for adolescents and young adults. ... treatment, underscoring the need to address barriers to care ... type 1 patients achieve optimal metabolic control. ...
(Date:5/21/2015)... 21, 2015  When Ryan Rendino first ... of his neck, he figured it was ... weeks off from weight lifting. ... A series of doctor ... to Michel Kliot, MD , a ...
Breaking Medicine Technology:Oxidative Stress Assays Market Worth $736.85 Million by 2020 2Oxidative Stress Assays Market Worth $736.85 Million by 2020 3Oxidative Stress Assays Market Worth $736.85 Million by 2020 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 2Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 3Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 4Study Reveals Poor Disease Control Among Adolescents and Young Adults with Type 1 Diabetes 5Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 2Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 3Northwestern Medicine Surgeons Develop New Approach to Removing Nerve Tumors 4
(Date:5/26/2015)... (PRWEB) May 26, 2015 U.S. Food ... in the United States are extensive and can be ... firm that helps medical device companies comply with FDA ... medical device companies navigate FDA requirements. , 1. ... the United States can be a lengthy process depending ...
(Date:5/26/2015)... 26, 2015 Carl W. Berk, M.D. ... Center in Pinehurst, N.C. have launched a Balloon Sinuplasty ... about chronic sinusitis and the benefits of Balloon Sinuplasty. ... used to determine if someone is a good candidate ... and other factors that can contribute to chronic nasal ...
(Date:5/25/2015)... Garden City, NY (PRWEB) May 26, 2015 ... honors Laquanis Hooker as a 2015-2016 inductee into ... is recognized with this prestigious distinction for leadership in ... for professional women, boasting more than 700,000 members and ... to welcome Laquanis into this exceptional group of professional ...
(Date:5/25/2015)... York, New York (PRWEB) May 25, 2015 ... distributor of patented products, announces the Hidee-Hose, an undergarment ... or shorts. , "The Global Women's Hosiery industry forecasts ... Scott J. Cooper, CEO and Creative Director of ... the hosiery industry is steering ahead and is expected ...
(Date:5/25/2015)... 2015 Thousands of DePuy Pinnacle ... in the federal multidistrict litigation now underway in ... to a Motion filed on May 20th, plaintiffs’ ... Case Management Order pertaining to the Limited Authorization ... Motion seeks the adoption of a new form ...
Breaking Medicine News(10 mins):Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 2Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 3Health News:FDA Medical Device Regulations: Top 10 Tips for Marketing a Device in the USA 4Health News:Pinehurst Surgical Sinus Center Launches Pinehurst Balloon Sinuplasty Website 2Health News:National Association of Professional Women Inducts Dr. Laquinas Hooked, D.D.S. of General Dentist, Into its VIP Professional Woman of the Year Circle 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 2Health News:For The Courtesy Of Women's Health And Looks - World Patent Marketing Presents A New Undergarment Patent 3Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 2Health News:Federal DePuy Pinnacle Hip Lawsuits Move Forward, as Plaintiffs Seek to Modify Order Pertaining to Health Authorizations 3
... occur on MySpace and Facebook, study finds , , FRIDAY, ... sites such as MySpace and Facebook have been singled ... most of the unwanted solicitation actually happens in chat ... , Even there, only 15 percent of children experience ...
... drugs (NSAIDs) are used to treat arthritis, which affects ... both prescription and over-the-counter (OTC) forms and are one ... Because of their widespread availability, patients may take both ... pain relief or because they are unaware that they ...
... with locally advanced laryngopharyngeal cancers who receive radical ... 12 months following treatment when compared with patients ... voice restoration, according to a study in the ... Radiation Oncology*Biology*Physics, the official journal of the American ...
... Aurora Health, Care and HealthEOS announced today that they have reached ... ... 1 As a result of the settlement,agreement, WPS customers that ... physicians and facilities through the end of,2008. The services provided to ...
... Smokers have a two-fold increased risk of developing ... cancers (CRC), according to a study published in Gastroenterology, ... Institute. , The results from this meta-analysis ... never smokers, 1.82 for ever versus never smokers and ...
... 1, 2008) - Amgen (NASDAQ: AMGN) and Wyeth Pharmaceuticals, ... from a retrospective analysis, which demonstrated that ENBREL reduced ... with moderate to severe plaque psoriasis following 12 weeks ... 10 times greater in the ENBREL treated group compared ...
Cached Medicine News:Health News:Social Networking Sites Safer Than IM or Chat Rooms 2Health News:Social Networking Sites Safer Than IM or Chat Rooms 3Health News:Taking more than 1 anti-inflammatory drug may lead to complications 2Health News:Larynx preservation preferred over total laryngectomy 2Health News:Wisconsin Physicians Service Insurance Corporation, Aurora Health Care and HealthEOS Announce Settlement Agreement 2Health News:Smoking can double risk of colorectal polyps 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 2Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 3Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 4Health News:New findings show Enbrel significantly reduced levels of C-reactive protein 5
Vaulted shank with guard....
... are individually adjusted for perfect focus where ... on paper. This, along with Keeler's wide ... that whatever the patient's pupil size, you ... of view. Lithium-ion technology provides a longer ...
... Beta 200 ophthalmoscope, the ... direct ophthalmoscope. Heine's aspherical ... #4,963,014) along with innovative ... make the Beta 200 ...
... Heine Beta 200S is the ... a combination of patented aspherical ... a range of corrective lenses ... in single diopter steps. A ...
Medicine Products: